Latest News

 Filter by Provider

Integra LifeSciences (IART) Q2 2025 earnings beat revenue and EPS estimates, but shares dipped pre-market. Strong performance in neurosurgery and wound care segments drives growth.

TreeHouse Foods (THS) beats Q2 2025 earnings with EPS of $0.17, exceeding estimates by 63%. Adjusted net sales and EBITDA also outperform, driving a 3.45% pre-market stock gain. Strong operational execution boosts investor confidence.

TAL Education Group (NYSE:TAL) reported Q1 FY2026 results with $575M revenue, missing estimates, but EPS of $0.07 beat forecasts. Shares rose 10.8% pre-market.

Shares rose, but from their worst close since 2022.

Titan International (TWI) Q2 2025 earnings miss estimates with $460.8M revenue and -$0.02 EPS. Stock down 13.4% in a month. No guidance provided.

CSW Industrials reports record Q1 2026 earnings, beating EPS estimates despite revenue miss. Shares surge 13% pre-market as investors focus on profitability.

CVS Health beats Q2 earnings and revenue estimates, raising full-year guidance. Shares surge 7% pre-market on strong Aetna and CVS Caremark performance.

SNDL Inc. beats Q2 2025 estimates with $244.99M revenue and $0.014 EPS, driving a 4.17% pre-market stock surge. Positive operating income signals growth in the competitive cannabis market.

Biotech company Biogen (NASDAQ:BIIB) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 7.3% year on year to $2.65 billion. Its non-GAAP profit of $5.47 per share was 41.3% above analysts’ consensus estimates.

Agios Pharmaceuticals (AGIO) reported Q2 2025 revenue of $12.46M, beating estimates, but EPS of -$1.93 missed forecasts. Shares fell 10.66% pre-market amid mixed financials and ongoing rare disease pipeline progress.

Cigna Group (NYSE:CI) beat Q2 revenue estimates but slightly missed on EPS, reaffirming full-year guidance. Shares rose 4.4% pre-market as investors focused on growth.

Kimco Realty (KIM) reported strong Q2 2025 EPS beat but slight revenue miss, raising full-year outlook. Shares dipped pre-market despite record small-shop occupancy and NOI growth.

Teleflex (NYSE:TFX) beats Q2 2025 estimates with $780.9M revenue and $3.73 EPS, driving a 15.9% pre-market surge. Strong growth in medical tech sector.

Exponent Inc (EXPO) excels with high profitability, strong cash flow, and steady growth, making it a top pick for long-term quality investors under the Caviar Cruise strategy.

KBR Inc. reported mixed Q2 2025 results with $1.95B revenue (up 6% YoY but below estimates) and $0.91 EPS (beating forecasts). Shares dipped as revenue miss offset EPS beat.

PG&E Corp (PCG) reported mixed Q2 2025 earnings, missing revenue estimates but reaffirming full-year guidance. Shares rose slightly in pre-market trading as investors focus on long-term outlook.

Railcar products and services provider Trinity (NYSE:TRN) fell short of the market’s revenue expectations in Q2 CY2025, with sales falling 39.8% year on year to $506.2 million. Its GAAP profit of $0.17 per share was 37% below analysts’ consensus estimates.

These three companies are on track to receive a prestigious distinction for consistently increasing their dividends.

Today's focus centres on corporate earnings, critical economic data releases, central bank decisions on interest rates, and developments in trade negotiations ahead of the new U.S. tariffs set to take effect this Friday.

Electronic equipment provider Vontier (NYSE:VNT) reported Q2 CY2025 results beating Wall Street’s revenue expectations, with sales up 11.1% year on year to $773.5 million. Revenue guidance for the full year exceeded analysts’ estimates, but next quarter’s guidance of $750 million was less impressive, coming in 0.7% below expectations. Its GAAP profit of $0.62 per share was 1.9% above analysts’ consensus estimates.

Eaton Corp. (ETN) is a top dividend stock with strong profitability, financial health, and consistent dividend growth, making it ideal for long-term investors.

Engineered components manufacturer for critical industries ITT Inc. (NYSE: ITT) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 7.3% year on year to $972.4 million. Its non-GAAP profit of $1.64 per share was 1.8% above analysts’ consensus estimates.

A major U.S. Army contract and strong analyst ratings underpin the bull case for Red Cat stock, whose recent price dip presents a compelling opportunity.

Diversified healthcare company CVS Health (NYSE:CVS) reported Q2 CY2025 results topping the market’s revenue expectations, with sales up 8.4% year on year to $98.92 billion. Its non-GAAP profit of $1.81 per share was 23.9% above analysts’ consensus estimates.

Discover how Dorman Products (DORM) aligns with Peter Lynch's GARP strategy—steady growth, fair valuation, strong financials, and a solid market position in automotive aftermarket parts.

August could be a particularly strong month for the S&P 500, driven by earnings season and the growth outlook; this examines five buys investors should consider

While you'll often hear these common rules about retirement, you should likely ignore them as they may not be right for you -- or for most people.

These companies are growing revenue faster than the rate of increase of the U.S. economy.

While the Fed voted to maintain the Fed Funds rate at 4.25-4.50%, Michelle Bowman and Christopher Wallace cast dissenting votes in favor of reducing rates.

Healthcare tech company Omnicell (NASDAQ:OMCL) announced better-than-expected revenue in Q2 CY2025, with sales up 5% year on year to $290.6 million. On top of that, next quarter’s revenue guidance ($295 million at the midpoint) was surprisingly good and 3.2% above what analysts were expecting. Its non-GAAP profit of $0.45 per share was 66.7% above analysts’ consensus estimates.

Document technology company Xerox (NASDAQ:XRX) beat Wall Street’s revenue expectations in Q2 CY2025, but sales were flat year on year at $1.58 billion. Its non-GAAP profit of $3 per share was significantly above analysts’ consensus estimates.

The Caviar Cruise strategy identifies high-quality stocks like Champion Homes (SKY), excelling in EBIT growth, ROIC, and low debt, ideal for long-term investors.

These two dividend-paying chip stocks could be worth a closer look in August.

The US Federal Reserve held rates steady as expected, but effectively dashed expectations of a rate cut at its September meeting, sending the US Dollar soaring.

Cruise company Norwegian Cruise Line (NYSE:NCLH) fell short of the market’s revenue expectations in Q2 CY2025, but sales rose 6.1% year on year to $2.52 billion. Its non-GAAP profit of $0.51 per share was in line with analysts’ consensus estimates.

ASML Holding NV (NASDAQ:ASML) combines strong fundamentals—high profitability, steady growth—with a potential technical turnaround, making it a compelling high-growth stock in semiconductor tech.

Medical technology company Teleflex (NYSE:TFX) announced better-than-expected revenue in Q2 CY2025, with sales up 2.3% year on year to $780.9 million. Its non-GAAP profit of $3.73 per share was 10.8% above analysts’ consensus estimates.

The premium yoga and athletic apparel maker is running out of room to grow.

Copper prices plunged 20% after Trump excluded refined copper from a 50% import tariff, ending a rally. Other factors and upcoming Chilean election may affect future prices.

Harley-Davidson will release a new entry-level motorcycle for $6000 in 2026, believes this would be profitable and accessible for customers.

Health insurance company Cigna (NYSE:CI) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 11.1% year on year to $67.18 billion. Its non-GAAP profit of $7.20 per share was 0.6% above analysts’ consensus estimates.

Certificates of deposit can be safe, but they're not perfect. Here are five CD investing drawbacks to understand before you lock in your cash.

Government and sustainable technology solutions company KBR (NYSE:KBR) missed Wall Street’s revenue expectations in Q2 CY2025, but sales rose 5.2% year on year to $1.95 billion. The company’s full-year revenue guidance of $8 billion at the midpoint came in 7.3% below analysts’ estimates. Its non-GAAP profit of $0.91 per share was 3% above analysts’ consensus estimates.